Gene · 7292
Papers4,164
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 4,164
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| RBPseg: Toward a complete phage tail fiber structure atlas. | Sci Adv | 2025 | 40479047 | PubTator, text mining | PubMed |
| Association between OX40L rs1234314 and rs844648 polymorphisms and unexplained recurrent pregnancy loss. | Mol Biol Rep | 2025 | 40465113 | PubTator, text mining | PubMed |
| miR-486-5p Inhibits eNOS and Angiogenesis in Cultured Endothelial Cells by Targeting MAML3. | J Cell Mol Med | 2025 | 40432288 | PubTator, text mining | PubMed |
| Curcumin-Induced Molecular Mechanisms in U-87 MG Glioblastoma Cells: Insights from Global Gene Expression Profiling. | Molecules | 2025 | 40430278 | PubTator, text mining | PubMed |
| OX40-OX40L Axis in Cutaneous T-Cell Lymphomas: Pathogenic, Prognostic, and Potential Therapeutic Perspectives. | Biomolecules | 2025 | 40427608 | PubTator, text mining | PubMed |
| A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40+ T cells. | Mar Life Sci Technol | 2025 | 40417257 | PubTator, text mining | PubMed |
| Synthetic Biology-Based Engineering Cells for Drug Delivery. | Exploration (Beijing) | 2025 | 40395752 | PubTator, text mining | PubMed |
| OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review. | Biologics | 2025 | 40331215 | PubTator, text mining | PubMed |
| Constructing a neural network model based on tumor-infiltrating lymphocytes (TILs) to predict the survival of hepatocellular carcinoma patients. | PeerJ | 2025 | 40292102 | PubTator, text mining | PubMed |
| Identifying TNFSF4low-MSCs superiorly treating idiopathic pulmonary fibrosis through Tregs differentiation modulation. | Stem Cell Res Ther | 2025 | 40254578 | PubTator, text mining | PubMed |
| Storage Temperature Affects Platelet Activation and Degranulation in Response to Stimuli. | Int J Mol Sci | 2025 | 40243579 | PubTator, text mining | PubMed |
| Integration of functional genomics and statistical fine-mapping systematically characterizes adult-onset and childhood-onset asthma genetic associations. | Genome Med | 2025 | 40205616 | PubTator, text mining | PubMed |
| Ultrasound-Energized OX40L-Expressing Biohybrid for Multidimensional Mobilization of Sustained T Cell-Mediated Antitumor Immunity and Potent Sono-Immunotherapy. | J Am Chem Soc | 2025 | 40200836 | PubTator, text mining | PubMed |
| The In Situ Structure of T-Series T1 Reveals a Conserved Lambda-Like Tail Tip. | Viruses | 2025 | 40143278 | PubTator, text mining | PubMed |
| Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs. | Int J Nanomedicine | 2025 | 40125432 | PubTator, text mining | PubMed |
| Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets. | Theranostics | 2025 | 40093895 | PubTator, text mining | PubMed |
| Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel). | Front Oncol | 2025 | 40083872 | PubTator, text mining | PubMed |
| Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer. | Front Oncol | 2025 | 40061889 | PubTator, text mining | PubMed |
| First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. | Invest New Drugs | 2025 | 40042547 | PubTator, text mining | PubMed |
| Integration of functional genomics and statistical fine-mapping systematically characterizes adult-onset and childhood-onset asthma genetic associations. | medRxiv | 2025 | 40034789 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7292/papers?page=9